Nytt svenskt alzheimerläkemedel i fas III – ”Vi angriper det största problemet”

En ny typ av alzheimerbehandling är på väg att utvecklas av svenska forskare. ”Det här lät först för bra för att vara sant, men efter tio års arbete har vi vant oss vid tanken”, säger KTH-professorn och serieentreprenören Mathias Uhlén.

Wegovy approved in the U.S. for treatment of liver disease

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Novo Nordisk’s drug Wegovy to treat the serious liver condition known as MASH. The decision strengthens the company’s position in the field of metabolic diseases.

Virology professor on the threat from X: ”The next pandemic could be worse“

The question is not if, but when we will be affected by a new unknown virus that causes yet another pandemic. Are we sufficiently prepared? "Absolutely not!", responds virologist Niklas Arnberg.

Mikael Kubista back with new venture after turbulent exit

Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership of his life's work – the company Tataa Biocenter. “Not only did they take our company away from us. They followed up by showering us with lawsuits,” he says.

Health politician Lina Nordquist: ”I find it hard to be idle”

She is the pharmacist and researcher who grew tired of the breakthroughs that never materialised and knowledge that never seemed to reach patients, so she decided to make a change from within. Life Science Sweden meets Lina Nordquist, Member of Parliament for the Liberals and their spokesperson on healthcare policy, to have a conversation about reality, politics, and the need for writing.

LINK Medical recruits Swedish CEO

The Norwegian Contract Research Organization LINK Medical has recruited Anders Göransson as the new CEO.

New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"

For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified insulin-producing cells that do not require immunosuppressive drugs. "A major immunological breakthrough," says Professor Per-Ola Carlsson, who leads the clinical study, to Life Science Sweden.

AZ gets approval for drug targeting rare disease – it may reduce cortisone dependence

AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.

Nobel Prize winner Torsten Wiesel turns 100: “Old men like me should use their experience to help the young”

In 1955, a young Torsten Wiesel jumped on a boat to the US and embarked on a fabulous career as a neuroscientist, crowned with a Nobel Prize for his work. Now 100 years old, he looks back on an intense life and his upbringing in Stockholm, Sweden, which shaped his desire to help the vulnerable in society.

“Conducting research at universities is becoming more and more like working at a research hotel”

The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at Lund University, about research policy, the constant hunt for funding in academia and what

KI’s freezer fiasco investigated: A chain of failures

A chain of combined technical and organisational shortcomings caused the freezer breakdown at the Karolinska Institute during the Christmas holidays, destroying more than 47,000 samples. This was the conclusion of an internal investigation.

Business Sweden: “Companies have a lot to offer in data-driven precision medicine”

Data-driven precision medicine can potentially solve major healthcare problems, states Business Sweden in a new report on the subject.

Novavax is developing a vaccine candidate against Covid-19 and seasonal flu

A combined vaccine against both Covid-19 and seasonal flu is showing promising results in studies, according to the American drug developer Novavax. The adjuvant, which forms an essential part of the vaccine, originates from Sweden.

A new international stem cell research centre has been created in Copenhagen

A new centre for stem cell research opened to the public in January. The Novo Nordisk Foundation backs the initiative with the ambition that the centre will advance new medical technology and new stem cell therapies.

Combining two drug delivery strategies to improve bioavailability

Danish researchers hope to increase the bioavailability of low solubility drugs.

Krönika: Collaboration across borders

Meet the governmental life science office

More clinical trials, promotion for digitisation and interoperability together with increased use of data generated by both healthcare and individuals. The duties of the Life Sciences office are plentiful.

Nya kit för genetiska fingeravtryck

Qiagens Investigator-serie tar fram genetiska fingeravtryck vid exempelvis brottsutredningar.

Anders Persson får brittiskt medicinpris

Anders Persson prisas med brittiskt forskningspris.

Nio etablerade forskare får EU-anslag

Passagereglering i blod-hjärnbarriären, riskfaktorer kring cancer och proteomanalyser är några forskningsområden som får anslag från Advanced Grant-programmet.

New automated solution for flexible molecular assays

The fully integrated Qiasymphony is a new automated platform for flexible molecular testing.

Samarbete med universitet ska gynna Novo

I Combine samarbetar sex svenska universitet för att skapa bättre förståelse kring inflammatoriska sjukdomar. Bolaget ska nu delta i ett projekt för att arbeta fram nya behandlingar av autoimmuna sjukdomar.

Einar Pontén, Managing Director, Merck Sequant

Why are you going to Scanlab+Biotech Forum?

Pfizer lays a chunky bid on Wyeth

The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.